Topic

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.

Bringing Collaboration to the Horizon Once More

Continuous improvements in technologies and services will help cold chain operators meet future industry demand.

Cold Comfort for Bio/Pharma

There are expectations that changes to pharma regulations in the EU, forming part of the regions broader strategy for the industry, will be positive and should offer flexibility for industry to advance through innovation.

Mapping Out Pharma’s Regulatory Future in Europe

Podcasts

Pharmaceutical Technology discussed the potential increased risk of counterfeit medicines in the UK post-Brexit and how blockchain could be a useful tool to tackle the issue.

Tackling Counterfeit Medicines

Solentim has announced the expansion of its European operations, with the establishment of a new entity in Ireland.

Solentim Establishes New European Entity

After Brexit there is an increased risk of the UK being exposed to counterfeit medicines, but regulations implementing blockchain as infrastructure technology could be the answer.

Blocking the Threat of Counterfeit Medicines

Despite the COVID-19 pandemic disruptions, with continued support and industry resilience, the European bio/pharma outlook for 2021 is positive.

The Outlook for a Year of Change

Bio/pharma continues preparations for a no-deal scenario as time for the UK and EU to agree upon a new deal runs out.

Dealing with No Deal

Industry wants clarification on compliance following the end of the Brexit transition period.

Calling for Clarity

Sean Milmo is a freelance writer based in Essex, UK.

EMA is facing a dilemma in trying to restore activities back to normal after relocating and the COVID-19 pandemic.  

Bio/Pharma and Brexit